

October 14, 2016

Announcements

Charles S. Fuchs, MD, MPH Named Director

I am pleased that Yale Cancer Center and Smilow Cancer Hospital will soon benefit from the excellent reputation and leadership of Dr. Charles S. Fuchs, who has been named our next Director and Physician-in-Chief. Charlie is an internationally known scientist and clinician with expertise in



gastrointestinal cancers. I believe his tenure here will come at the perfect time as the cancer center and hospital focus on building the infrastructure and sustainability needed to support our recent rapid growth, and prepare us for our next stage of development. Charlie will begin his tenure here on January 1 and I will work with him throughout his transition to Yale over the coming months to help minimize any impact to our daily operations.

[Read More >>](#)

New Care Center Oncologist

from the desk of

Peter G. Schulam, MD, PhD

Director, Yale Cancer Center
and Physician-in-Chief,
Smilow Cancer Hospital (Interim)

Yale NewHaven Health

Smilow Cancer Hospital

Yale

**CANCER
CENTER**

A Comprehensive Cancer Center Designated
by the National Cancer Institute

Recent News


Read recent articles featuring experts from
Yale Cancer Center

[News Center >>](#)

LATEST ARTICLES:

Khanh Nguyen,

MD recently joined Yale Cancer Center and Smilow Cancer Hospital as a clinician in our Derby Care Center. Dr. Nguyen joins us from the University of Pittsburgh Medical Center (UPMC) where he completed his fellowship in Hematology/Oncology.



Dr. Nguyen received his medical degree from the Medical College of Georgia and his residency at the University of Virginia Health System. His recent research includes the evaluation of endoplasmic reticulum stress modulator and autophagy inhibitor as a potential therapeutic option for pancreatic cancer. We are excited to welcome Dr. Nguyen to the Smilow community!

Screening Summit

The Smilow Screening & Prevention Program will host a Screening Summit for physicians on November 9 at 5:30pm at Yale's West Campus. The Summit will provide community physicians and healthcare providers with brief updates on screening guidelines for 4 common cancer types and the implemented recommendations at Smilow Cancer Hospital. Please [RSVP](#) to join us at this important event.

[Learn More >>](#)

Notables

Rogério Lilenbaum, MD has been named Chair of the Data Safety Monitoring Board (DSMB) for **Alliance Foundation Trials (AFT)**. AFT is a research organization that develops and conducts cancer clinical trials, working closely with pharmaceutical partners, research collaborators, and the Alliance for Clinical Trials in Oncology scientific investigators and its institutional member network.

Andrea Kliss has joined the Smilow administration team in the office of Dr. Rogério Lilenbaum as a



Our Own Words

[Read More >>](#)



Smiles for Smilow Supports Teens with Cancer

[Read More >>](#)



Cancer clinical trials offer hope to more patients

[Read More >>](#)

Program Coordinator. Andrea received her MA in Applied Clinical Psychology from Pennsylvania State University and comes to us with a strong program development and quality improvement background. She recently worked as a Cancer Program Coordinator for Catholic Health Initiatives, where she developed and executed cancer prevention screening programs within the community.

Research in the News

Study of ramucirumab plus pembrolizumab shows promise in NSCLC

In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, presented the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress.

This is the first study to combine ramucirumab, a VEGFR2 antibody, with pembrolizumab, a PD-1 antibody, to target both angiogenesis and immunosuppression simultaneously. Individually, both drugs have shown clinical activity in multiple tumor types.

[Read More >>](#)

Researchers find genes behind aggressive ovarian and endometrial cancers

In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.

The collaborative research team - which included experts in gynecological cancer, genomics, pathology and computational biology- performed a comprehensive genetic analysis of ovarian and endometrial CSs. The team collected tumors from 68 women affected with ovarian and uterine CSs to try to determine the molecular basis of the tumor's aggressive behavior. They sequenced all the genes from the tumors and identified mutations that are crucial for these tumors to grow. The team also studied the copy number variations - genes



Why men should get screened for prostate cancer

[Read More >>](#)



Yale Developing Text System To Remind Breast Cancer Patients To Take Medication

[Read More >>](#)



From Rags to Riches: Bladder Cancer Research Rife With New Approaches

[Read More >>](#)

Join Smilow Cancer Hospital on Facebook

that are not mutated but are amplified in the tumors to give them a growth advantage over normal tissues.

[Read More >>](#)


New model for understanding myeloma

In a new study, Yale professors Madhav Dhodapkar, Richard Flavell, and their co-authors describe new mouse models, wherein mice carry human versions of six genes that are essential for growth of tumor cells. They found that when the humanized mice were injected with tumor and non-tumor cells, both cell types were able to grow. The finding provides a potential new approach to understanding how myeloma develops and how to prevent it.

[Read More >>](#)

New Member Profile: Patty Lee, MD

Co-Leaders Peter Glazer and Joann Sweasy are pleased to welcome Patty Lee, MD, Associate Professor in Pulmonary, Critical Care & Sleep Medicine, to the Radiobiology and Radiotherapy (RR) Research Program. Dr. Lee's lab has had long-standing interests in oxidant-mediated mechanisms of lung injury and repair. Specifically, she uses genetic mouse models and molecular techniques to define the role of innate immune receptors, mitogen-activated protein kinases (MAPKs), and heat shock proteins as key regulators of oxidant-mediated injury as well as cytoprotective lung responses. Collaborating with the Rimm, Glazer, and Sweasy Labs, the Lee Lab has generated exciting new data linking BRCA1 and p16 to lung DNA repair responses in smoking-induced lung diseases. Dr.




LATEST POSTS:

Dr. Meena Moran's research interests focus on outcomes in breast cancer patients treated with radiation therapy, ethnic variations in breast cancer, and quality improvement in breast health care delivery. Her most recent study highlights the benefits of a radiation boost for women with ductal carcinoma in situ (DCIS) breast cancer.



[Read More >>](#)

Check out this fantastic piece by Ashley Makar, who is receiving her treatment at Smilow. We can all learn something from reading her words, which challenge the way that we frame the narrative surrounding cancer. Thank you, Ashley, for not being



afraid to speak up about this important issue.

[Read More >>](#)

Download our latest Yale Cancer Answers podcast to learn about breast cancer

Lee welcomes the opportunity to deepen her research program in age- and smoke-related lung pathology, and also hopes to serve as a lung-resource for other YCC members.

Employee Profile: Megan Vicario, RN

Known as the 'Multiple Myeloma Queen,' Megan Vicario, RN, infusion nurse at the North Haven Care Center, works primarily with Dr. Martin Katz and patients diagnosed with hematological malignancies, many of them multiple myeloma patients.

However, she also helps to treat and triage patients with various solid tumors such as breast, lung, and gastrointestinal cancers.

Megan administers chemotherapy treatments, handles prescription authorizations, and triages patient calls. A large portion of her day includes patient education and symptom management. A lot is done to manage symptoms at home, in order to avoid any unnecessary office visits and increase quality of life. Megan commented that the North Haven Care Center is one of the highest volume satellite clinics, and they can see anywhere from 25 to 55 patients in a day.

Much of Megan's passion for oncology nursing comes from her father's diagnosis with lung cancer when she was just a teenager. He was a non-smoker and very young when he was diagnosed. "Watching the compassionate care that my father received made me realize how important nurses are not just to the patient, but to the entire family unit," said Megan. "As my father's health started to decline, he had a home hospice nurse that we became very close to, and she was there with us when he passed away."



screening and the newest imaging techniques with Dr. Laura Horvath.



[Read More >>](#)

When Marjorie was diagnosed with breast cancer, she knew the journey ahead wouldn't be easy; you see, Marjorie had already survived surgery, radiation, chemotherapy, and a hysterectomy to beat cervical cancer. But that didn't keep Marjorie from keeping a positive outlook, anchored in her buddhist practice.

"My members and friends continuously chanted with me and were very supportive," she said.



[Read More >>](#)

Researchers at Yale Cancer Center are testing a new virus they think may have an effect against chemotherapy-resistant ovarian cancer. The virus has proved itself against brain tumors in animal subjects, eliminating them completely, and Anthony N. Van den Pol, PhD, who leads the study, feels confident about the virus' effectiveness against ovarian cancer.

"Based on our very promising preliminary data, we expect that the virus will not only selectively infect and destroy ovarian cancer cells but lead to a dramatic increase in the lifespan of test animals beyond conventional chemotherapy," Van den Pol said.

Megan commented that is very important for her to develop a relationship with patients early and be there for them throughout the stages of their disease. With new treatment regimens, multiple myeloma patients are often required to come in once or twice a week, which is thankfully increasing survival rates. "It is wonderful to see these patients doing well," said Megan.

Diane Corjulo, RN, BSN, Clinical Program Manager for the Smilow Cancer Hospital Care Centers, commented, "Patients and families share that Megan is a wonderful and exceptional nurse. She is not afraid to discuss her concerns for her patients and she has a very nice way of collaborating with the provider. She is a strong advocate for patient safety and for policy and practice in her clinical setting."

Funding and Award Opportunities

All current funding opportunities are archived on the Yale Cancer Center website, and searchable by topic, funding agency, and due date. Please check the site often for new opportunities.

[Learn More >>](#)

Yale Pepper Center Letters of Intent

The Yale Pepper Center is soliciting letters of intent from full-time faculty members at Yale with interests and expertise relevant to aging research who would be interested in submitting a career development proposal (if currently within 4 years of first faculty appointment), a pilot project proposal, or a research development project.

Letter of Intent Deadline: October 17, 2016

[Learn More >>](#)

Melanoma Research Alliance Grants

The **Melanoma Research Alliance (MRA)** is pleased to announce a **Request for Proposals (RFP)** for high-impact translational research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Young Investigator Awards, Established Investigator Awards, Pilot



EVEN IF THE VIRUS WORKS ONLY A QUARTER AS WELL IN HUMANS ... THIS COULD BE A GIANT STEP FORWARD IN THE TREATMENT OF THIS LIFE-THREATENING MALADY.



[Read More >>](#)

Follow Yale Cancer Center on Twitter

Follow us on [twitter](#)

LATEST TWEETS:

Changes in depression symptoms tied to lung cancer survival #lscsm @YaleCancer's Mark Lazenby comments

Register to attend our symposium for young adults living with cancer and #cancersurvivors this Saturday

New paper from @YaleCancer in @PNASNews identifies #genes behind aggressive #ovariancancer & endometrial cancer

Hormone Therapy for Men with #ProstateCancer w/ Cardiac History Evaluated

Phase I trial of ramucirumab plus pembrolizumab shows promise in NSCLC, @DrRoyHerbstYale presents #ESMO16 #lscsm

Smiles for #Smilow brings smiles to the faces of preteen and teen #cancer patients year round! #worldsmileday @YNHH

Congratulations to .@AneesChagpar on her @CTBHI grant! Dr. Chagpar is doing great work to help all patients. #bcsm

Awards, and Academic-Industry Partnership Awards.

Application Deadline: October 21, 2016

[Learn More >>](#)

Women's Health Research at Yale 2016-2017 Pilot Project Program

Pilot Project Awards: Up to \$35,000 over one or two years for research designed to meet a pressing need in women's health with a clearly described path to direct clinical or public health utility.

Wendy U. and Thomas C. Naratil Pioneer Award:

Up to \$50,000 in funding over one or two years to initiate new investigations that are highly inventive or close to a major breakthrough in advancing women's health.

Application Deadline: October 27, 2016

[Learn More >>](#)

Pancreatic Cancer Action Network - Frederick National Laboratory For Cancer Research KRAS Fellowship

The Pancreatic Cancer Action Network and the National Cancer Institute (NCI) Frederick National Laboratory for Cancer Research (FNLCR) have joined together to award two Fellowships to support research projects that are directly relevant and applicable to pancreatic cancer and KRAS and that align with the RAS Initiative that is being spearheaded by FNLCR.

Deadline for Application: October 27, 2016

[Learn More >>](#)


Department of Defense Breast Cancer Research Program Funding Opportunities for Fiscal Year 2016 (FY16)


The Fiscal Year 2016 (FY16) Defense Appropriations Act provides \$120 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research to accelerate progress toward ending breast cancer.

Breakthrough Award

Funding Levels 1 and 2:

 Charles S. Fuchs, MD, MPH named Director @YaleCancer and Physician-in-Chief of Smilow Cancer Hospital @YNHH

 Join us now live on Facebook for In our Own Words, an essay series written and read by our patients

 With cancer comes new experiences, new challenges & the greatest of compassionate, caring people...

Closer to Free

closer to free

The fund to advance cancer research and enhance patient care

Upcoming Events

October 14; 12PM

Endocrine Grand Rounds

BCMM 206/208

Mechanisms of Immune Therapy for Cancer: What the Endocrinologist Should Know

Scott Gettinger, MD

[Read More >>](#)

October 15; 8AM

IMPACT: A Conference for Young Adults Living with Cancer and Beyond

Park Street Auditorium

Tara Sanft, MD and Samantha Watson, SamFund

[Read More >>](#)

October 17; 11AM

YCC Radiobiology and Radiotherapy Research Program

SHM I-304

Nanoparticles for Site-specific Genome Editing in Utero

Adele Ricciardi

[Read More >>](#)

October 18; 9:30AM

- Investigators at all academic levels (or equivalent)
- Postdoctoral fellows are eligible and encouraged to apply

Application Deadline: November 3, 2016
[Learn More >>](#)

Pathway to Leadership Grant

The Pathway to Leadership Grant is a grant of up to five years totaling up to \$600,000 that is designed to build future leadership in the pancreatic cancer research community by supporting a highly promising postdoctoral or clinical research fellow during his or her mentored research and career development, continuing through his or her early phase of independence.

Application Deadline: November 15, 2016
[Learn More >>](#)

Office of Disease Prevention Call for Nominations for Early-Stage Investigator Award

The Office of Disease Prevention (ODP) at the National Institutes of Health invites submissions for the ODP Early-Stage Investigator Award. This inaugural award will recognize early-career prevention scientists who have already made substantial, outstanding research contributions to their respective fields and are poised to become future leaders in prevention research.

Deadline for Nominations:
 November 15, 2016
[Learn More >>](#)

Emerging Questions in Cancer Systems Biology (U01)

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment.

Application Receipt/Submission
Date(s): November 18, 2016
[Read More >>](#)

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Pathology Research in Progress Talk

TAC N-107
 TBA
 Kate Nyhan, MLS and Philip Askenase, MD
[Read More >>](#)

October 18; 12PM

Yale Cancer Center Grand Rounds

Park Street Auditorium
Investigating T cell function in genetically-engineered mouse models of cancer
 Nikhil Joshi, PhD
Outpatient Oncology Palliative Care: Partnering in patient-centered cancer care
 Mark Swidler, MD
[Read More >>](#)

October 18; 6PM

YNHH Community Health Education

SRC, Cronin Auditorium
How Much Do You Know About Breast Health?
 Andrea Silber, MD
[Read More >>](#)

October 19; 12Pm

Pediatric Grand Rounds/20th Annual Dorothy M. Horstmann Lecture

Fitkin Amphitheatre
Virus Specific T-Cells for the Treatment of Malignancy
 Cliona Rooney, PhD
[Read More >>](#)

October 19; 12PM

Yale's Working Women Network Health Series

Luce Hall Auditorium
Get in Touch with Breast Health - For Life!
 Betsy Nilan
[Read More >>](#)

October 20; 9AM

Therapeutic Radiology Grand Rounds

Smilow LL505
CBIT: Supporting Your MedTech Innovation
 Margaret Cartiera, PhD
M&M Case: Late Radiation Esophageal Toxicity
 John Stahl, MD
[Read More >>](#)

Application Receipt/Submission

Date(s): November 30, 2016

[Read More >>](#)

Pancreatic Cancer Action Network Translational Research Grant

This grant supports an independent investigator leading a cross-disciplinary team conducting translational research that has as its endpoint the development of a pancreatic cancer assessment, prevention or treatment modality

Deadline for Application: December 1, 2016

[Read More >>](#)

ALSF Research Grants 2017 Funding Opportunities

Alex's Lemonade Stand Foundation (ALSF) has evolved from the front yard lemonade stand of cancer patient Alexandra "Alex" Scott (1996-2004) into a national fundraising movement for childhood cancer research.

Open for Applications (funding to start in 2017):

- Innovation Grant - Letter of Intent, Deadline: Nov. 1, 2016 - Submit Now!
- Epidemiology Grants - Deadline: Dec. 15, 2016 - Apply Now!
- Young Investigator Grants - Deadline: Dec. 15, 2016 - Apply Now!

[Learn More >>](#)

Recent Publications

A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma.

Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA.

JAMA Oncol. 2016 Oct 13.

[Read More >>](#)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.

Wong CR, Nguyen MH, Lim JK. World J Gastroenterol. 2016 Oct 7;22(37):8294-8303.

[Read More >>](#)

October 20; 2:30PM

Smilow Cancer Genetics and Prevention Program Seminar

Cancer Genetics and Prevention Program, Suites 107-109

National Society of Genetic Counselors (NSGC) 35th Annual Education Conference Update

Arpita Neogi, CGC, Rebecca Leshay, CGC, and Cassy Guiden, CGC

[Read More >>](#)

October 21; 1PM

YCC Developmental Therapeutics Research Program

SHM I-304

PLEKHA5: A Key Mediator of Brain Tropism in Melanoma Metastasis

Lucia Jilaveanu, MD, PhD

[Read More >>](#)

October 24; 11AM

YCC Radiobiology and Radiotherapy Research Program

SHM I-304

Nuclear Role for the Fanconi Anemia Pathway Protein, FANCI, in rDNA transcription

Samuel Sondalle

[Read More >>](#)

October 25; 9:30AM

Pathology Research in Progress Talk

TAC N-107

TBA

Kathryn Ferguson, PhD and Hai Feng Zhang, PhD

[Read More >>](#)

October 25; 12PM

YCC Grand Rounds/John Murren, MD Memorial Lecture

Park Street Auditorium Immunotherapy for Lung Cancer: Charting a Course for Cure

Karen Kelly, MD

[Read More >>](#)

October 25; 4PM

Human and Translational Immunology Seminars

TAC N-203

Immuno-Therapy for Non-Small Cell Lung Cancer: Predictive Markers and Combination Therapy

Metabolite and Microbiome Interplay in Cancer Immunotherapy.

Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G. *Cancer Res.* 2016 Oct 11.

[Read More >>](#)

Diagnosis of cancer as an emergency: a critical review of current evidence.

Zhou Y, Abel GA, Hamilton W, Pritchard-Jones K, Gross CP, Walter FM, Renzi C, Johnson S, McPhail S, Elliss-Brookes L, Lyratzopoulos G. *Nat Rev Clin Oncol.* 2016 Oct 11.

[Read More >>](#)

Epigenetics in Cancer: A Hematological Perspective.

Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. *PLoS Genet.* 2016 Oct 10;12(10):e1006193.

[Read More >>](#)

Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.

Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu MH, Borsotti C, Zhang L, Branagan A, Eynon E, Manz MG, Flavell RA, Dhodapkar MV. *Nat Med.* 2016 Oct 10.

[Read More >>](#)

Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis.

Kilic O, Pamies D, Lavell E, Schiapparelli P, Feng Y, Hartung T, Bal-Price A, Hogberg HT, Quinones-Hinojosa A, Guerrero-Cazares H, Levchenko A. *Lab Chip.* 2016 Oct 7.

[Read More >>](#)

Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell LungCancer.

Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. *J Thorac Oncol.* 2016 Oct 5.

[Read More >>](#)

Roy Herbst, MD, PhD

[Read More >>](#)

October 27; 9AM

Therapeutic Radiology Grand Rounds

Smilow LL505

State of Yale New Haven Hospital and Health System

Thomas Balcezak, MD, MPH and Richard D'Aquila, MPH

[Read More >>](#)

October 27; 12PM

YCC Global Oncology Seminar Series

SHM I-116

Reducing Mortality of What Will be the #2 Cause of Cancer Death Five Years from Now

Harvey Risch, MD, PhD

[Read More >>](#)

October 27; 12:30PM

Pathology Grand Rounds

LMP 1094

Epigenetics: A Driver of DNA Copy Number and Drug Response

Johnathan Whetstone, PhD

[Read More >>](#)

October 27; 2:30PM

Smilow Cancer Genetics and Prevention Program Seminar

Cancer Genetics and Prevention Program, Suites 107-109

TBA

[Read More >>](#)

October 28; 7:30AM

Surgery Grand Rounds / 4th Annual Stephan Ariyan, MD, MBA Lectureship

Fitkin Amphitheatre, LMP 1094

TBA

Charles Balch, MD

[Read More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Marketing

Roles of defective ALDH2 polymorphism on liver protection and cancer development.

Matsumoto A, Thompson DC, Chen Y, Kitagawa K, Vasiliou V. Environ Health Prev Med. 2016 Oct 6.

[Read More >>](#)

Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma.

Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Scherthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF. J Gastrointest Surg. 2016 Oct 6.

[Read More >>](#)

Exposure to inorganic arsenic can lead to gut microbe perturbations and hepatocellular carcinoma.

Choiniere J, Wang L. Acta Pharm Sin B. 2016 Sep;6(5):426-429.

[Read More >>](#)

Toward automated assessment of health Web page quality using the DISCERN instrument.

Allam A, Schulz PJ, Krauthammer M. J Am Med Inform Assoc. 2016 Oct 5.

[Read More >>](#)

Greedy outcome weighted tree learning of optimal personalized treatment rules.

Zhu R, Zhao YQ, Chen G, Ma S, Zhao H. Biometrics. 2016 Oct 4.

[Read More >>](#)

Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma.

Kuo P, Manes RP, Schwam ZG, Judson BL. Otolaryngol Head Neck Surg. 2016 Oct 4.

[Read More >>](#)

Continuous home care reduces hospice disenrollment and hospitalization after hospice enrollment.

renee.gaudette@yale.edu



Wang SY, Aldridge MD, Canavan M, Cherlin E,
Bradley E. J Pain Symptom Manage. 2016 Sep 30.

[Read More >>](#)